Needham & Company LLC started coverage on shares of Omada Health (NASDAQ:OMDA - Free Report) in a report published on Tuesday, Marketbeat reports. The firm issued a buy rating and a $23.00 target price on the stock.
OMDA has been the topic of several other research reports. Canaccord Genuity Group initiated coverage on Omada Health in a research report on Tuesday. They issued a "buy" rating and a $27.00 price target on the stock. The Goldman Sachs Group assumed coverage on Omada Health in a research note on Tuesday. They issued a "buy" rating and a $29.00 target price on the stock. Finally, Wall Street Zen upgraded Omada Health to a "hold" rating in a research note on Monday, June 16th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.57.
Check Out Our Latest Analysis on OMDA
Omada Health Stock Performance
NASDAQ OMDA traded up $0.53 during trading on Tuesday, reaching $18.63. The company's stock had a trading volume of 344,526 shares, compared to its average volume of 1,585,299. Omada Health has a twelve month low of $14.14 and a twelve month high of $28.40.
Omada Health Company Profile
(
Get Free Report)
Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
Read More
Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
